{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:49:04Z","timestamp":1767649744324},"reference-count":22,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00266","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T22:18:08Z","timestamp":1504217888000},"page":"1447-1453","source":"Crossref","is-referenced-by-count":12,"title":["Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database"],"prefix":"10.1248","volume":"40","author":[{"given":"Mayu","family":"Takeyama","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Tohoku University"},{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimie","family":"Sai","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Imatoh","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Segawa","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Hirasawa","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Tohoku University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Tohoku University"},{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF. A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports. Drug Saf.<\/i>, 39<\/b>, 561\u2013575 (2016).","DOI":"10.1007\/s40264-016-0409-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of \u2018surprise\u2019 adverse drug reactions. Drug Saf.<\/i>, 30<\/b>, 143\u2013155 (2007).","DOI":"10.2165\/00002018-200730020-00004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf.<\/i>, 26<\/b>, 293\u2013301 (2003).","DOI":"10.2165\/00002018-200326050-00001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int. J. Med. Sci.<\/i>, 10<\/b>, 796\u2013803 (2013).","DOI":"10.7150\/ijms.6048"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, Sasaoka S, Tahara K, Takeuchi H, Kinosada Y. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J. Pharm. Health Care Sci.<\/i>, 1<\/b>, 34 (2015).","DOI":"10.1186\/s40780-015-0035-2"},{"key":"6","unstructured":"6) Narushima D, Kawasaki Y, Takamatsu S, Yamada H. Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model. PeerJ<\/i>, 4<\/b>, e1753 (2016)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fujiwara M, Kawasaki Y, Yamada H. A pharmacovigilance approach for post-marketing in Japan using the Japanese adverse drug event report (JADER) database and association analysis. PLOS ONE<\/i>, 11<\/b>, e0154425 (2016).","DOI":"10.1371\/journal.pone.0154425"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Abe J, Umetsu R, Mataki K, Kato Y, Ueda N, Nakayama Y, Hane Y, Matsui T, Hatahira H, Sasaoka S, Motooka Y, Hara H, Kato Z, Kinosada Y, Inagaki N, Nakamura M. Analysis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database. J. Pharm. Health Care Sci.<\/i>, 2<\/b>, 14 (2016).","DOI":"10.1186\/s40780-016-0048-5"},{"key":"9","unstructured":"9) U.S. Food and Drug Administration. \u201cSafety information, Xgeva (denosumab).\u201d: \u2039http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm303740.htm\u203a, issued June 2015."},{"key":"10","unstructured":"10) Medicines and Healthcare products Regulatory Agency (MHRA). \u201cDenosumab: updated recommendations.\u201d: \u2039https:\/\/www.gov.uk\/drug-safety-update\/denosumab-updated-recommendations\u203a, issued September 25, 2014."},{"key":"11","unstructured":"11) Pharmaceuticals and Medical Devices Agency. \u201cDear Healthcare Professional Letter of Rapid Safety Communication, RANMARK.\u201d: \u2039https:\/\/www.pmda.go.jp\/files\/000153380.pdf\u203a, issued September 11, 2012."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus<\/i> zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol.<\/i>, 29<\/b>, 1125\u20131132 (2011).","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"13","unstructured":"13) Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr. Med. Res. Opin.<\/i>, 29<\/b>, 1067\u20131073 (2013)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Dami\u00e3o R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur. J. Cancer<\/i>, 51<\/b>, 1812\u20131821 (2015).","DOI":"10.1016\/j.ejca.2015.05.016"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care<\/i> (Basel), 9<\/b>, 332\u2013336 (2014).","DOI":"10.1159\/000368844"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol.<\/i>, 10<\/b>, 257\u2013275 (2014).","DOI":"10.2217\/fon.13.211"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF. A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports. Drug Saf.<\/i>, 39<\/b>, 561\u2013575 (2016).","DOI":"10.1007\/s40264-016-0409-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hanatani T, Sai K, Tohkin M, Segawa K, Saito Y. Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. Int. J. Clin. Pharm.<\/i>, 37<\/b>, 537\u2013545 (2015).","DOI":"10.1007\/s11096-015-0097-0"},{"key":"19","unstructured":"19) Hanatani T, Sai K, Tohkin M, Segawa K, Antoku Y, Nakashima N, Yokoi H, Ohe K, Kimura M, Hori K, Kawakami J, Saito Y. Evaluation of two Japanese regulatory actions using medical information databases: a \u2018Dear Doctor\u2019 letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel. J. Clin. Pharm. Ther.<\/i>, 39<\/b>, 361\u2013367 (2014)."},{"key":"20","unstructured":"20) Ooba N, Yamaguchi T, Kubota K. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug Saf.<\/i>, 34<\/b>, 329\u2013338 (2011)."},{"key":"21","unstructured":"21) Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf.<\/i>, 30<\/b>, 891\u2013898 (2007)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H, Nakayama T, Okugawa S, Sugimura Y, Tomita M, Takahashi Y. Bias in spontaneous reporting of adverse drug reactions in Japan. PLOS ONE<\/i>, 10<\/b>, e0126413 (2015).","DOI":"10.1371\/journal.pone.0126413"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/9\/40_b17-00266\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:51:24Z","timestamp":1570063884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/9\/40_b17-00266\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00266","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}